The Adherence Crisis in Psychiatry: Why So Many Stop Treatment Early
Clinically reviewed by Wendy Delgado, PA-C
Reviewed November 16, 2026 · Last updated November 16, 2026
Key Takeaways
- Stopping antidepressants early is common. In a U.S. national survey, 42% of adults stopped within the first month and only 28% stayed on treatment past 90 days, and a 2023 Italian study found only about a third stayed adherent for six months.
- People stop for understandable reasons: side effects, feeling better, not seeing benefits yet, and too little guidance or follow-up between visits.
- Stopping once you feel better has a cost. In a review of 31 trials of people who had improved on an antidepressant, relapse averaged 41% after stopping versus 18% for people who continued.
- Clear instructions, regular follow-up, and collaborative care help people stay on treatment, and measurement-based care helped people reach remission faster in a randomized trial.
You start an antidepressant. The first couple of weeks bring a queasy stomach or restless sleep, and you’re not sure it’s doing anything. Your next appointment is weeks away, so you decide on your own whether to keep going. Many people stop right there, and it’s one of the most predictable failure points in mental health care.
Antidepressants work by gradually changing how brain cells communicate, and that adaptation takes weeks. Side effects often show up before the benefits do, so the hardest stretch of treatment comes right at the start. Getting through it takes precision: the right dose, the right expectations, and someone checking how the medication is actually affecting you.
The medications themselves are well studied. A 2003 Lancet review of 31 randomized trials found that staying on an antidepressant after improving cut the odds of relapse by 70% compared with stopping. The results are real, and the science is well established.
But a prescription is only the beginning of treatment, and at Siggy we think the weeks after the first appointment matter as much as the appointment itself.
This guide looks at how often people stop psychiatric medication early, why it happens, what it costs, and the care changes shown to help. The pattern is a predictable gap in how care is delivered, and closing it is a question of evidence.
What This Page Covers
- How Common Is It to Stop Antidepressants Early?
- Why Do People Stop Their Medication?
- What Happens When Treatment Stops Too Soon?
- Is This a Patient Problem or a System Problem?
- What Actually Helps People Stay on Treatment?
- How Siggy Fits In
- Start Your Anonymous Intake
How Common Is It to Stop Antidepressants Early?
Stopping early is very common. Clinicians call staying on a medication as prescribed “adherence,” and across studies, early stopping is the norm rather than the exception. Here’s what two studies found, with the national survey measured at two points in time.
| Study | Time Point | What Happened |
|---|---|---|
| U.S. national survey, 829 adults | First 30 days | 42.4% stopped |
| U.S. national survey, 829 adults | Past 90 days | Only 27.6% continued |
| Primary care study, 155 patients | Months 1 to 3 | 28% stopped in month 1, 44% by month 3 |
The national figures come from a household survey analysis using data from 1996 to 2001, and the month 1 and month 3 figures come from a primary care study. The national survey also found that early stopping was more common among people with lower incomes and less education, which suggests access plays a role alongside personal circumstances.
The pattern hasn’t faded. In a 2023 Italian study of 8,235 adults prescribed antidepressants by their general practitioners, only 32.4% stayed adherent for six months or more over a year of follow-up, and 68.7% discontinued treatment during that time.
Why Do People Stop Their Medication?
The reasons are human and understandable. In a qualitative study of 30 patients taking antidepressants, side effects were one of the major barriers to staying on treatment, while seeing real benefits and having a good relationship with a provider were among the biggest reasons people kept going.
Feeling better is another common turning point. That’s why “keep taking it even after you feel better” is one of the core messages research has linked to people staying on treatment.
The care itself plays a role too. A 2021 review of adherence research found that prescriber-side factors, such as choosing a poorly tolerated medication, using a complicated regimen, or overlooking medical and family history, are linked to people stopping. When side effects start, you’re often on your own until the next appointment, and stopping can feel like the only lever you control.
If any of that sounds like your experience, you’re seeing what happens when a treatment that takes weeks to work meets care that checks in every few months. It isn’t a personal failing.
What Happens When Treatment Stops Too Soon?
For people who stop once they feel better, the biggest cost is relapse. In the Lancet review, people who stopped their antidepressant after improving relapsed at an average rate of 41%, compared with 18% for people who stayed on it. The protective effect appeared to last up to three years, though most trials ran about 12 months.
Those trials studied people who had already improved, so they speak most directly to the decision to stop once you feel better. People who stop in the first few weeks face a different cost: they often never find out whether the medication would have helped.
Relapse can mean more than feeling bad again. It can mean starting over with a new medication, waiting for a new appointment, and losing ground at work and at home, which is why any decision to stop should be planned with a prescriber.
Is This a Patient Problem or a System Problem?
The evidence points largely to the system. In a JAMA study of patients starting SSRIs, 72% of physicians said they usually ask patients to continue for at least six months. Only 34% of patients remembered being told that, and 56% said they received no instructions about duration at all.
That gap had consequences. Patients who believed they should take their medication for less than six months were about three times more likely to stop. Patients who talked with their physician about side effects were about half as likely to stop, and having fewer than three follow-up visits was linked to stopping treatment.
In the national survey, people who also received psychotherapy were far more likely to continue past the first month (68.0% versus 43.7%). Contact, conversation, and follow-up keep people on track, and those are features of how care is designed.
What Actually Helps People Stay on Treatment?
Simple guidance makes a measurable difference. In that primary care study, patients were more likely to stay on treatment in the first month when they heard five specific messages:
- Take the medication every day.
- Expect it to take 2 to 4 weeks to notice an effect.
- Keep taking it even after you feel better.
- Don’t stop without checking with your prescriber.
- Know exactly how to get your questions answered.
Structured, connected care helps too. A Cochrane review of 79 trials found that collaborative care, where a care manager and prescriber work together and follow up proactively, improved depression and anxiety outcomes compared with usual care and was linked to better medication use.
Tracking symptoms and acting on them improves results once people are in treatment. In a randomized trial of 120 adults with moderate to severe depression, measurement-based care, meaning treatment adjusted based on regular symptom ratings, led to remission in 73.8% of patients compared with 28.8% in standard care, with no difference in dropout or side effects. It was a single, relatively small trial, and its benefit was faster improvement rather than fewer people stopping, but it shows what happens when someone checks whether treatment is working and adjusts quickly.
How Siggy Fits In
“No one checks in to see if it’s actually working.” Siggy was built around that gap. It starts with a free, anonymous intake, with no name or email required. A licensed prescriber reviews your intake before anything is prescribed, and you get a summary you can keep and share, so you don’t have to retell your story every time you see someone new.
Once you’re on a plan, Siggy is built for the stretch between appointments where most people quietly stop. Daily check-ins help your prescriber see how the medication is treating you, plain-language education built from FDA labeling explains which side effects tend to pass and which mean you should contact your clinician, and Siggy offers evidence-based coping skills and strategies for the hard early weeks. Those skills support your treatment, and they don’t replace therapy with a licensed therapist. If you’re feeling better and thinking about stopping, your prescriber can help you decide whether it’s the right time and guide a gradual taper.
Siggy isn’t a crisis line. If you’re thinking about harming yourself, call or text 988, or call 911. This article is for education and isn’t a substitute for care from a licensed clinician. It reflects sources available as of November 2026.
Start Your Anonymous Intake
Most people who stop psychiatric medication early do so for understandable reasons, in a care model that leaves them alone during the hardest weeks. The fix is well documented: clear expectations, regular follow-up, conversations about side effects, and care that tracks symptoms and adjusts quickly. If you’re early in treatment, our guide to the first 8 weeks on an antidepressant walks through it week by week. If you’ve started and stopped before, or you want support that stays with you after the first appointment, start your anonymous intake with Siggy. It’s free, there’s no name or email required, a licensed prescriber reviews your intake before anything is prescribed, and your summary is yours to keep.
Mental healthcare should stay with you between appointments.
Siggy combines daily check-ins with clinician-supervised care so your treatment plan can respond to what is actually happening.
Start anonymously. A real doctor reviews every clinical decision. HIPAA-compliant.
Frequently Asked Questions
What percentage of people stop taking antidepressants early?
A large share of people stop antidepressants within the first few months. In a U.S. national survey, 42.4% of adults who started an antidepressant for depression stopped within 30 days, and only 27.6% continued for more than 90 days. A separate primary care study found that 44% had stopped by the third month.
Why do people stop taking psychiatric medication so quickly?
Common reasons include side effects, feeling better and assuming the medication is no longer needed, and not seeing benefits yet. Care factors matter too, including poorly tolerated medications, complicated regimens, unclear instructions about how long to continue, and too few follow-up visits.
What happens when someone stops an antidepressant too early?
Stopping after you have improved, before your prescriber recommends it, raises the risk of relapse. In a review of 31 randomized trials, people who stopped their antidepressant after improving relapsed at an average rate of 41%, compared with 18% for people who continued, a 70% reduction in the odds of relapse with continued treatment.
Is the adherence crisis the patient's fault?
The adherence crisis is largely a care-model problem. In one study, 72% of physicians said they usually ask patients to continue antidepressants for at least six months, but only 34% of patients remembered being told that, and fewer than three follow-up visits was linked to stopping treatment.
What helps people stay on their medication?
Clear, specific guidance and steady follow-up help the most. Patients who heard five simple messages, including that antidepressants take weeks to work and shouldn't be stopped without checking in, were more likely to stay on treatment. Collaborative care and measurement-based care also improve outcomes.
How should I stop an antidepressant if I want to?
Talk with your prescriber before stopping so you can plan the timing and taper together. Stopping suddenly can cause discontinuation symptoms and raises relapse risk, and your prescriber can help you decide whether now is the right time and how to reduce the dose gradually.
Sources
- Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661. PubMed 12606176
- Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry. 2006;163(1):101-108. doi:10.1176/appi.ajp.163.1.101
- Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Medical Care. 1995;33(1):67-74. doi:10.1097/00005650-199501000-00006
- Di Nicola M, Dell’Osso B, Cipelli R, et al. Adherence to, and persistence of, antidepressant therapy in patients with major depressive disorder: results from a population-based study in Italy. Current Neuropharmacology. 2023;21(3):727-739. doi:10.2174/1570159X20666220411092813
- Ho SC, Jacob SA, Tangiisuran B. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS One. 2017;12(6):e0179290. doi:10.1371/journal.pone.0179290
- Solmi M, Miola A, Croatto G, et al. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Brazilian Journal of Psychiatry. 2021;43(2):189-202. doi:10.1590/1516-4446-2020-0935
- Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409. doi:10.1001/jama.288.11.1403
- Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Database of Systematic Reviews. 2012;10:CD006525. doi:10.1002/14651858.CD006525.pub2
- Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. American Journal of Psychiatry. 2015;172(10):1004-1013. doi:10.1176/appi.ajp.2015.14050652